Audit (A-01-11-02509)

Executive Summary

Axerion Therapeutics (the grantee) claimed costs of $951,000 that were allowable under the terms of the grant and applicable Federal regulations; however, the grantee did not account for $54,000 in proceeds that it earned from the sale of equipment that was purchased for the grant. The National Institutes of Health awarded the grantee $3 million under the American Recovery and Reinvestment Act of 2009.